医学
前列腺癌
围手术期
前列腺
雄激素剥夺疗法
肿瘤科
内科学
前列腺切除术
变形杆菌
泌尿科
抗雄激素
癌症
雄激素
泌尿系统
癌症研究
化疗
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-06-09
卷期号:: OF1-OF1
标识
DOI:10.1158/2159-8290.cd-nw2026-0068
摘要
For people with localized, high-risk prostate cancer, treatment with 6 months of apalutamide and androgen deprivation therapy (ADT) both before and after surgery reduces the risk of metastases and death compared with perioperative ADT alone, according to results of the phase III PROTEUS trial. At 5 years, 78.2% of patients who received apalutamide plus ADT were alive and free from metastasis, compared with 73.5% in the ADT only group.
科研通智能强力驱动
Strongly Powered by AbleSci AI